Products in the Pipeline

---

Our Anti-CD70 CAR platform is designed to target CD70-expressing solid and hematological malignancies with exceptional specificity and potency. Engineered for enhanced persistence, tumor infiltration, and resistance to immune suppression, it offers a powerful approach to overcoming treatment resistance. With integrated safety and performance optimization, our CD70 CAR therapy represents a next-generation solution for durable and effective cancer immunotherapy.

Our Anti-PSCA in-vivo CAR-M platform is designed to reprogram macrophages within the body to selectively target and eliminate PSCA-expressing prostate and pancreatic cancers (PDAC). By harnessing the innate tumor-homing and phagocytic abilities of macrophages, it promotes direct tumor clearance and immune activation. This novel approach offers a potent, accessible, and durable immunotherapy for hard-to-treat solid tumors.

Our dual-targeting CAR-T therapy against PSCA and Mesothelin is specifically engineered to address the heterogeneity and immune evasion of pancreatic ductal adenocarcinoma (PDAC). By simultaneously targeting two key tumor-associated antigens, it enhances tumor recognition, infiltration, and cytotoxic efficacy. This innovative approach aims to overcome the immunosuppressive microenvironment of PDAC, offering a powerful and durable therapeutic option for one of the most challenging solid tumors.

Our Anti-CD19 in-vivo CAR-T platform is engineered to selectively eliminate pathogenic B cells driving autoimmune disorders such as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), ANCA-associated Vasculitis (AAV), and Idiopathic Inflammatory Myopathies (IIM). By enabling precise in-vivo reprogramming of T cells, it offers a scalable, patient-friendly alternative to conventional cell therapy. This breakthrough approach aims to restore immune balance and achieve long-lasting remission in severe autoimmune diseases.

Our VSV-based viral tagging platform leverages engineered vesicular stomatitis virus to selectively tag cancer cells with Mesothelin, enhancing their visibility to Mesothelin-directed CAR-T cells. This strategy transforms antigen-low or resistant tumors like mesothelioma, ovarian cancer and PDAC into CAR-T–susceptible targets, enabling broader and more effective tumor eradication. By combining oncolytic virotherapy and targeted immunotherapy, it represents a synergistic approach to overcoming tumor immune escape.

Our CLDN18.2 CAR-T therapy is designed to precisely target Claudin 18.2–expressing solid tumors, including gastric, pancreatic, and other gastrointestinal cancers. Engineered for high specificity, persistence, and resistance to immunosuppression, it effectively combats the challenges of solid tumor microenvironments. This next-generation CAR-T platform offers a potent and durable therapeutic option for patients with limited treatment alternatives.